Isconova has appointed Russell Greig, currently a member of its board, as acting CEO for the company. He will assume this position on October 1, 2011 to replace Lena Söderström, who will leave Isconova at the end of September. The recruitment process to find a permanent CEO has been initiated.

“Lena has made great strides during her time as CEO. Under her management, Isconova has taken several important steps through the implemented strategy change with an increased focus on human vaccines, the listing on First North as well as the agreements made within both human and veterinary vaccines. Going forward, the board’s assessment is that the company needs leadership with significant international experience and a strong track record in business development, and so a search is now underway to find a CEO with these specific skills,” said Ulf Tossman, chairman of the board of Isconova.

Russell Greig has more than 30 years experience in different positions within the pharmaceutical industry, most recently as president of SR One, GlaxoSmithKline’s Corporate Venture Group. During his years at GSK, Russell’s roles included senior vice president of worldwide business development, general manager of UK Pharmaceuticals and president of Pharmaceutical International.

Isconova AB is a leading international vaccine adjuvant company. Isconova has vast knowledge of vaccine systems and the company develops vaccines together with partners in the human and veterinary markets.